Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement.

Llovet JM, Mauro E, Rimassa L, Mazzaferro V, Pinter M, Kelley RK, Chan SL, Kulik L, Pillai A, Roberts L, Sangro B, Casanovas T, Kaplan DE, Vogel A, Yarchoan M, Finn RS, Meyer T, Singal AG

Open source

DOI: 10.1038/s41571-026-01160-z
Published: 2026 Aug
Container: Nature reviews. Clinical oncology
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41571-026-01160-z,
  title = {Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement.},
  author = {Llovet JM and Mauro E and Rimassa L and Mazzaferro V and Pinter M and Kelley RK and Chan SL and Kulik L and Pillai A and Roberts L and Sangro B and Casanovas T and Kaplan DE and Vogel A and Yarchoan M and Finn RS and Meyer T and Singal AG},
  year = {2026},
  journal = {Nature reviews. Clinical oncology},
  doi = {10.1038/s41571-026-01160-z},
  url = {https://doi.org/10.1038/s41571-026-01160-z}
}

RIS

TY  - JOUR
TI  - Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement.
AU  - Llovet JM
AU  - Mauro E
AU  - Rimassa L
AU  - Mazzaferro V
AU  - Pinter M
AU  - Kelley RK
AU  - Chan SL
AU  - Kulik L
AU  - Pillai A
AU  - Roberts L
AU  - Sangro B
AU  - Casanovas T
AU  - Kaplan DE
AU  - Vogel A
AU  - Yarchoan M
AU  - Finn RS
AU  - Meyer T
AU  - Singal AG
PY  - 2026
JO  - Nature reviews. Clinical oncology
DO  - 10.1038/s41571-026-01160-z
UR  - https://doi.org/10.1038/s41571-026-01160-z
ER  -

APA

JM, L., E, M., L, R., V, M., M, P., RK, K., SL, C., L, K., A, P., L, R., B, S., T, C., DE, K., A, V., M, Y., RS, F., T, M., & AG, S. (2026). Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement.. Nature reviews. Clinical oncology. https://doi.org/10.1038/s41571-026-01160-z

Source records

pubmed · retrieved 2026-09-26T04:01:21.130Z
europe-pmc · retrieved 2026-09-26T04:01:21.142Z